Timothy Arens - SurModics VP of Corporate Devel. and Strategy
| SRDX Stock | USD 39.56 0.23 0.58% |
VP
Mr. Timothy J. Arens is Chief Financial Officer, Vice President Finance, Principal Financial Officer of the Company. Previously, from August 2011 to February 2013, Mr. Arens has served as the Companys Vice President of Finance and interim Chief Financial Officer. From October 2010 to August 2011, Mr. Arens served as the Companys General Manager, In Vitro Diagnostics. Mr. Arens joined the Company in February 2007 as Director, Business Development, and served in finance roles of increasing responsibility, including as Senior Director of Financial Planning and Analysis since 2019.
| Age | 57 |
| Tenure | 5 years |
| Address | 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523 |
| Phone | 952 500 7000 |
| Web | https://www.surmodics.com |
Timothy Arens Latest Insider Activity
Tracking and analyzing the buying and selling activities of Timothy Arens against SurModics stock is an integral part of due diligence when investing in SurModics. Timothy Arens insider activity provides valuable insight into whether SurModics is net buyers or sellers over its current business cycle. Note, SurModics insiders must abide by specific rules, including filing SEC forms every time they buy or sell SurModics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Timothy Arens over three months ago Disposition of 18447 shares by Timothy Arens of SurModics at 33.2 subject to Rule 16b-3 | ||
Timothy Arens over three months ago Acquisition by Timothy Arens of 8323 shares of SurModics subject to Rule 16b-3 |
SurModics Management Efficiency
Return On Tangible Assets is likely to rise to -0.1 in 2024. Return On Capital Employed is likely to rise to -0.03 in 2024. At this time, SurModics' Other Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 60.7 M in 2024, whereas Total Assets are likely to drop slightly above 142.8 M in 2024. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | VP Age | ||
| David JD | Anika Therapeutics | 52 | |
| McAlister II | Integer Holdings Corp | 54 | |
| Marc Began | Axogen Inc | 56 | |
| Ian McLeod | Anika Therapeutics | N/A | |
| Jonathan Walker | LivaNova PLC | N/A | |
| Jim Rodberg | Sight Sciences | N/A | |
| Geoffrey Gillespie | Orthofix Medical | N/A | |
| Johonna CPA | CONMED | 51 | |
| Steve Tamayo | Sight Sciences | N/A | |
| Jason Somer | Inogen Inc | 56 | |
Management Performance
| Return On Equity | -0.0967 | ||||
| Return On Asset | -0.0066 |
SurModics Leadership Team
Elected by the shareholders, the SurModics' board of directors comprises two types of representatives: SurModics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SurModics. The board's role is to monitor SurModics' management team and ensure that shareholders' interests are well served. SurModics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SurModics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joel Suiter, Director Development | ||
| Timothy Arens, VP of Corporate Devel. and Strategy | ||
| Charles Olson, Sr. VP and General Manager of Medical Device | ||
| Gary Maharaj, CEO and President and Director | ||
| Joseph Stich, VP and General Manager of In-Vitro Diagnostics | ||
| Gordon JD, General Legal | ||
| Gordon Weber, General Legal | ||
| Teryl Sides, Senior Interventions | ||
| John Manders, Corporate Controller and Principal Accounting Officer | ||
| Gregg Sutton, Vice President - Research & Development |
SurModics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SurModics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0967 | ||||
| Return On Asset | -0.0066 | ||||
| Profit Margin | (0.09) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 556.57 M | ||||
| Shares Outstanding | 14.33 M | ||||
| Shares Owned By Insiders | 3.79 % | ||||
| Shares Owned By Institutions | 83.07 % | ||||
| Number Of Shares Shorted | 330.95 K | ||||
| Price To Earning | 69.21 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.